In this report, we discuss how autoimmune conditions and associated
immunocompromise may impact diagnostic utility of molecular screening
tools for mycobacterial infection. Imaging, molecular screening, and
clinical judgment are required to rule out disease in the
immunocompromised, especially in an acute setting